Prothena (NASDAQ:PRTA) Stock: Insider William Scully Purchases 140,000 Shares

Prothena Corporation plc (NASDAQ:PRTA) major shareholder William Scully bought 140,000 shares of the firm’s stock in a transaction that occurred on Monday, November 9th. The stock was bought at an average price of $8.53 per share, with a total value of $1,194,200.00. Following the transaction, the insider directly owned 977,000 shares in the company, valued at $8,333,810. This represents a 16.73% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Prothena Trading Up 2.0%

Prothena stock opened at $8.73 on Thursday. Prothena Corporation plc has a 52 week low of $7.73 and a 52 week high of $11.80. The stock has a market cap of $448.29 million, a price-to-earnings ratio of -18.19, a PEG ratio of 1.83 and a beta of -0.20. The company’s 50-day moving average price is $8.60 and its two-hundred day moving average price is $9.18.

Prothena (NASDAQ:PRTA) last issued its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.09). Prothena had a negative return on equity of 9.98% and a negative net margin of 45.44%. The company had revenue of $0.62 million during the quarter, compared to analyst estimates of $9.58 million. Research analysts expect that Prothena Corporation plc will post 0.13 earnings per share for the current fiscal year.

Trending Headlines about Prothena

Here are a few of the latest headlines about PRTA:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and $30 price target. Separately, a Zacks article noted that the consensus target implies roughly 120% upside from recent levels, although it cautioned that price targets can be unreliable. Zacks article
• Neutral Sentiment: A short-interest report listed short interest at zero shares and a 0.0-day ratio, despite describing a large increase; the figures provide no clear directional signal. Short-interest information
• Negative Sentiment: HC Wainwright lowered several future EPS forecasts, including FY2027–FY2029 and FY2030, while maintaining its Buy rating. It also cut its Q4 2026 estimate to a $0.44-per-share loss from a $0.38 loss. Prothena’s latest reported quarter also missed expectations: EPS was a $0.32 loss versus a $0.23 loss forecast, and revenue was $0.62 million versus $9.58 million expected. Analyst estimates and results

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on PRTA. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Prothena in a research note on Friday, July 24th. UBS Group restated a “buy” rating on shares of Prothena in a report on Friday, July 24th. Weiss Ratings cut Prothena from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, October 29th. Finally, Wall Street Zen lowered Prothena from a “buy” rating to a “hold” rating in a report on Saturday, July 25th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Institutional Trading of Prothena

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC bought a new position in shares of Prothena in the third quarter valued at $239,000. Chicago Partners Investment Group LLC lifted its position in shares of Prothena by 59.8% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 25,779 shares of the biotechnology company’s stock valued at $211,000 after acquiring an additional 9,650 shares during the last quarter. Pinnacle Associates Ltd. boosted its stake in shares of Prothena by 6.2% during the 3rd quarter. Pinnacle Associates Ltd. now owns 61,507 shares of the biotechnology company’s stock worth $515,000 after acquiring an additional 3,589 shares in the last quarter. Versant Capital Management Inc boosted its stake in shares of Prothena by 179.1% during the 3rd quarter. Versant Capital Management Inc now owns 5,704 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 3,660 shares in the last quarter. Finally, Engineers Gate Manager LP bought a new stake in shares of Prothena during the 2nd quarter worth $404,000. 97.08% of the stock is owned by institutional investors and hedge funds.

About Prothena

Prothena Corporation plc is a clinical-stage biotechnology company developing treatments for diseases associated with protein misfolding and dysfunction. Its research focuses on using antibodies and other biologic approaches to target proteins implicated in neurological and systemic disorders. The company’s pipeline has included programs for Parkinson’s disease, Alzheimer’s disease and AL amyloidosis. Its investigational therapies include prasinezumab, developed in collaboration with Roche, and programs targeting amyloid beta and transthyretin-related disease.